ea0019p230 | Pituitary | SFEBES2009
Luck S
, Carroll P
, Chambers J
, Powrie J
Ergot derived dopamine agonist therapy (EDDAT) has recently been associated with fibrotic cardiac valvulopathy in patients with Parkinsons disease. These patients received a cumulative dose of 28006700 mg of cabergoline for an average duration of two years. This has raised concerns about the use of these agents in patients with prolactinomas and has led to the recent EMEA/MHRA guidance that all patient being treated with EDDA should undergo surveillance echocardiog...